HC Wainwright Issues Optimistic Estimate for AGIO Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Analysts at HC Wainwright increased their FY2030 EPS estimates for Agios Pharmaceuticals in a research note issued to investors on Tuesday, June 2nd. HC Wainwright analyst E. Bodnar now anticipates that the biopharmaceutical company will post earnings of $2.73 per share for the year, up from their prior forecast of $2.57. HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.17) per share.

Several other brokerages have also recently issued reports on AGIO. The Goldman Sachs Group upped their price objective on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a research note on Wednesday, April 1st. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Friday, March 27th. Citigroup upped their price objective on shares of Agios Pharmaceuticals from $38.00 to $46.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. JPMorgan Chase & Co. upped their price objective on shares of Agios Pharmaceuticals from $31.00 to $36.00 and gave the company a “neutral” rating in a research note on Monday, April 6th. Finally, Wall Street Zen raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, March 22nd. Six analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $41.44.

Agios Pharmaceuticals Stock Down 5.3%

AGIO stock opened at $26.51 on Wednesday. The stock has a market capitalization of $1.58 billion, a P/E ratio of -3.66 and a beta of 0.59. Agios Pharmaceuticals has a 52 week low of $22.24 and a 52 week high of $46.00. The firm has a 50-day simple moving average of $29.68 and a 200-day simple moving average of $28.96.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) EPS for the quarter, topping analysts’ consensus estimates of ($1.81) by $0.12. The business had revenue of $20.75 million during the quarter, compared to analysts’ expectations of $13.30 million. Agios Pharmaceuticals had a negative net margin of 639.84% and a negative return on equity of 34.11%. The business’s quarterly revenue was up 137.7% compared to the same quarter last year.

Hedge Funds Weigh In On Agios Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the company. Bellevue Group AG boosted its holdings in Agios Pharmaceuticals by 3.5% in the 3rd quarter. Bellevue Group AG now owns 3,714,736 shares of the biopharmaceutical company’s stock valued at $149,110,000 after purchasing an additional 124,586 shares during the last quarter. State Street Corp boosted its holdings in Agios Pharmaceuticals by 37.4% in the 4th quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company’s stock valued at $84,604,000 after purchasing an additional 845,433 shares during the last quarter. Erste Asset Management GmbH boosted its holdings in Agios Pharmaceuticals by 1.4% in the 4th quarter. Erste Asset Management GmbH now owns 2,804,900 shares of the biopharmaceutical company’s stock valued at $76,343,000 after purchasing an additional 40,000 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Agios Pharmaceuticals by 485.5% in the 3rd quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock valued at $99,203,000 after purchasing an additional 2,049,287 shares during the last quarter. Finally, Commodore Capital LP boosted its holdings in Agios Pharmaceuticals by 0.6% in the 3rd quarter. Commodore Capital LP now owns 2,338,287 shares of the biopharmaceutical company’s stock valued at $93,859,000 after purchasing an additional 13,287 shares during the last quarter.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 3,262 shares of the business’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total value of $113,224.02. Following the transaction, the insider directly owned 46,829 shares in the company, valued at $1,625,434.59. The trade was a 6.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Krishnan Viswanadhan sold 2,959 shares of the business’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $27.80, for a total transaction of $82,260.20. Following the completion of the transaction, the insider owned 5,141 shares in the company, valued at $142,919.80. The trade was a 36.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 15,582 shares of company stock worth $520,405 in the last 90 days. 5.40% of the stock is owned by insiders.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.